NeRRe Therapeutics raises £20 million in a Series B2 financing round
July 07, 2021 07:00 ET
|
NeRRe Therapeutics
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...
NeRRe Therapeutics raises £20 million in a Series B2 financing round
July 07, 2021 02:00 ET
|
NeRRe Therapeutics
NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
June 07, 2019 07:00 ET
|
NeRRe Therapeutics
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough
June 07, 2019 02:00 ET
|
NeRRe Therapeutics
NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...